DYN•benzinga•
Why Is Dyne Therapeutics Stock Soaring On Monday?
Summary
Dyne Therapeutics reported promising Phase 1/2 trial data for DYNE-101 in myotonic dystrophy type 1 and DYNE-251 in Duchenne muscular dystrophy. Improvements in splicing correction, myotonia, muscle strength, and dystrophin expression were observed.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 20, 2024 by benzinga